Company Filing History:
Years Active: 2008-2016
Title: Guenther Adolf: Innovator in Cancer Therapy
Introduction
Guenther Adolf is a prominent inventor based in Vienna, Austria. He has made significant contributions to the field of cancer therapy, particularly through his innovative methods and treatments. With a total of 3 patents, his work focuses on improving patient outcomes in cancer treatment.
Latest Patents
One of Guenther Adolf's latest patents is titled "Stratification of pancreatic and ovarian cancer patients for susceptibility to therapy with PTK2 inhibitors." This invention outlines a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor. The method involves detecting the expression of the E-cadherin protein in a cancer sample, where an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates susceptibility to treatment. The patent also describes a method of treating patients based on their E-cadherin IRS score and provides a framework for screening effective PTK2 inhibitors.
Another notable patent involves "Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them." This patent focuses on anti-FAP antibodies and immunoconjugates, along with pharmaceutical compositions that utilize these conjugates in cancer therapy.
Career Highlights
Guenther Adolf is currently associated with Boehringer Ingelheim International GmbH, where he continues to advance his research and innovations in cancer treatment. His work has been instrumental in developing therapies that target specific cancer markers, thereby enhancing treatment efficacy.
Collaborations
Throughout his career, Guenther has collaborated with notable colleagues, including Karl-Heinz Heider and Elinborg Ostermann. These collaborations have fostered a productive environment for innovation and research in cancer therapy.
Conclusion
Guenther Adolf's contributions to cancer therapy through his patents and collaborations highlight his commitment to improving patient care. His innovative approaches continue to pave the way for advancements in the treatment of cancer.